louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05790629: Three Dimensional Evaluation of Apexogenesis of Immature Young Permanent Teeth With Different Endodontic Material
Official title: Three Dimensional Evaluation of Apexogenesis of Immature Young Permanent Teeth With Different Endodontic Tri-calcium Silicate-Based Putties: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Deep Carious Young 1st Permanent Molar With Open Apex
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2023-03-30
Enrollment: 48
Sex: ALL
Minimum age (years): 6
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized Clinical Trial using Three Dimensional Evaluation of Apexogensis of immature young permanent teeth with Different Endodontic Tri-calcium Silicate-Based Putties

Detailed description: Treatment of immature permanent teeth has always been challenging in endodontics, not only because of their wide-open root apices but also because of the thin underdeveloped dentinal walls.Apexogenesis falls under the category of vital pulp therapy (VPT) procedure to maintain pulp vitality, induce dentin bridge formation and encourage continued root maturation.

To overcome the drawbacks of tricalcium silicate-based cements, a range of bioactive endodontic cements have been developed.

EndoSequence BC RRM-Fast Set Putty and NeoPutty (NuSmile, Houston, TX, USA) are the two materials evaluated in this study.

Eligibility criteria: Inclusion Criteria:

* First permanent molar with pulpitis.
* Sufficient tooth structure for placing rubber dam.
* Presence of open apex.
* Short root length.

Exclusion Criteria:

* Insufficient tooth structure that need post and core.
* Presence of swelling.
* Presence of sinus tract.
* Presence of root fracture.
* Presence of root crack.
* Presence of external or internal root resorption.
* Presence of periapical pathosis.
* Presence of root calcification.

Primary outcomes:
measure: asymptomatic
timeFrame: one year
Secondary outcomes:
measure: complete root maturation
timeFrame: one year
Other outcomes:
measure: maintain pulp vitality
timeFrame: one year
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar university dental clinics and 6 October university dental clinics
state: Choose A State Or Province
Study officials:
References:
Clinical trial NCT00110929: Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
Official title: A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: End Stage Renal Disease
Keywords: Sensipar®
Secondary HPT
Mimpara®
Cinacalcet
calcimimetic
End-Stage Renal Disease (ESRD)
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2005-05-17
Enrollment: 850
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to study the efficacy and safety of AMG 073 in patients with kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also have secondary hyperparathyroidism (HPT).


Eligibility criteria: Inclusion Criteria: - Completed one of the qualifying studies (i.e., patient previously took part in an Amgen study investigating the drug AMG 073 and its effects on secondary hyperparathyroidism \[HPT\]; in particular parathyroid hormone \[PTH\], calcium and phosphorus levels in blood associated with kidney failure) - Must agree to use, in the opinion of the principal investigator, highly effective contraceptive measures throughout the study Exclusion Criteria: - Pregnant or nursing females - Experienced a myocardial infarction within 3 months before day 1 - Have an unstable medical condition, defined as having been hospitalized, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator

Primary outcomes:
measure: Examine PTH and Ca x P control when cinacalcet is administered in the setting of flexible dosing of vitamin D sterols.
Secondary outcomes:
measure: Examine safety and tolerability of cinacalcet.
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
citation: Sprague SM, Evenepoel P, Curzi MP, Gonzalez MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep;4(9):1465-76. doi: 10.2215/CJN.06141108. Epub 2009 Aug 20.
Clinical trial NCT02878629: Mandibular Advancement Devices Tali® in Patients With Syndrome of Obstructive Sleep Apnea and Hypopneas
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Syndrome of Obstructive Sleep Apnea and Hypopneas
Lead sponsor: ONIRIS
Sponsor class: INDUSTRY
First posted: 2016-08-25
Enrollment: 254
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients \> 18 years treated with Mandibular Advancement Device Tali® from at least 2 years and at the latest 5 years.

Brief summary: The main objective is to evaluate middle term compliance (≥ 2 years) of the Mandibular Advancement Devices Tali® in patients with Syndrome of Obstructive Sleep Apnea and Hypopneas.


Eligibility criteria: Inclusion Criteria:

* Patients \> 18 years treated with Mandibular Advancement Device Tali® from at least 2 years and at the latest 5 years.
* Patients who agree to participate to the study.

Primary outcomes:
measure: compliance (no stop of the Mandibular Advancement Device)
timeFrame: 2 years or more after the beginning of device
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Liberal cabinet
Study officials:
References:
Clinical trial NCT00915629: Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Vaginal Candidiasis
Lead sponsor: Larena SAS
Sponsor class: INDUSTRY
Collaborators: name: BioFortis
First posted: 2009-06-08
Enrollment: 134
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Vulvovaginal candidiasis (VVC) is a common infection among women that is associated with considerable morbidity and health-care cost. 75% of women will suffer of Candida infection for at least one time in their life. 20% of women who suffer from VVC will have ≥ 4 episodes of VVC during the one year prior to the survey. 80% of these VVC are caused by Candida albicans. Current treatments, based on imidazoles, face many failures or recurrences. The type of probiotic Lactobacillus may participate in the prevention of recurrent vulvo-vaginitis in reducing the proliferation of intestinal Candida albicans, its adherence to the vaginal walls, the potentiation of its propagation. The primary objective of this study was to investigate if our supplementary treatment could improve the initial cure rate after vaginal econazole therapy.


Eligibility criteria: Inclusion Criteria:

* women
* 18-65 years
* suffering from 4 or more episodes of VVC during the 1 year prior to the survey
* all participants must be symptomatic with a microbiological proof of infection with candida albicans

Exclusion Criteria:

* Pregnancy, lactation being
* HIV infection, chemotherapy or illness serious enough to induce an immune deficiency. A diabetic patient will not be systematically excluded;
* Vulvo-vaginitis and / or cervicitis specific, defined in a bacteriological examination by the presence of herpes virus, gonorrhea or chlamydia;
* Bacterial Vaginosis or Trichomonas;
* Use of vaginal probiotics in the months before inclusion;
* Cure of probiotics in the months preceding the inclusion;
* Contraindication to Gynopévaryl LP

Primary outcomes:
measure: The primary objective of this study was to investigate if Lactibiane candisis 5M supplementation could lengthen the time to relapse after initial local cure
timeFrame: 9 months
Secondary outcomes:
measure: The secondary objective of this study is to compare the number of recurrence in the lactibiane candisis 5M group versus placebo.
timeFrame: 2, 3, 6 and 9 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Pileje
Study officials:
name: AZOULAY Catherine, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cooke G, Watson C, Deckx L, Pirotta M, Smith J, van Driel ML. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD009151. doi: 10.1002/14651858.CD009151.pub2.
Clinical trial NCT05794529: Lung Tumor Protein Synthesis Rates in Lung Cancer Patients
Official title: Characterizing Tissue Protein Synthesis Rates of Non-small Cell Lung Carcinomas in Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2023-04-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: In total, we will recruit 30 lung cancer patients (diagnosed with a NSCLC) scheduled to undergo surgery. The nature and the risks of the experimental procedures will be explained to all subjects before their informed consent will be obtained. All subjects will be recruited through contact with their Surgeon at the Department of surgery at Zuyderland Medical Centre, Heerlen.

Brief summary: The current study will recruit lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to lung tumor tissue to establish the remodeling characteristics of healthy versus cancerous lung tissues. We will also examine whether tissue protein synthesis rates of non-small cell lung carcinomas are associated with various tumor- (i.e., size, subclassification) and patient-derived (i.e., inflammation, lung function, smoking status, and smoking history) parameters.


Eligibility criteria: Inclusion Criteria:

1. Aged 18-65 years
2. Compos mentis
3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy

Exclusion Criteria:

1. Neoadjuvant chemo- or radiotherapy in the past four weeks
2. Use of systemic steroids in the past four week
3. Insulin-dependent diabetes mellitus
4. Pregnancy

Primary outcomes:
measure: Lung tumor fractional synthetic rate
timeFrame: 5 days prior to surgery
measure: Lung tissue fractional synthetic rate
timeFrame: 5 days prior to surgery
measure: Muscle tissue fractional synthetic rate
timeFrame: 5 days prior to surgery
Secondary outcomes:
measure: Plasma glucose concentrations
timeFrame: Baseline
measure: Plasma insulin concentrations
timeFrame: Baseline
measure: Plasma GH concentrations
timeFrame: Baseline
measure: Plasma IGF-1 concentrations
timeFrame: Baseline
measure: Plasma IGFBP-1 concentrations
timeFrame: Baseline
measure: Plasma IGFBP-3 concentrations
timeFrame: Baseline
measure: Plasma CRP concentrations
timeFrame: Baseline
measure: Plasma IL-1 concentrations
timeFrame: Baseline
measure: Plasma IL-6 concentrations
timeFrame: Baseline
measure: Plasma IL-10 concentrations
timeFrame: Baseline
measure: Plasma TNF-alpha concentrations
timeFrame: Baseline
Other outcomes:
Locations:
city: Heerlen
country: Netherlands
facility: Zuyderland Medical Center
state: Limburg
Study officials:
References:
Clinical trial NCT02965729: Our Lifestyles Our Lives
Official title: Our Lifestyles, Our Lives: Obesity Treatment and Physical Activity Promotion for Underserved Children and Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Obesity
Weight Loss
Keywords: behavior goals
self-monitoring
pedometer
physical activity
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
Collaborators: name: Our Lady of the Lake Hospital
name: American Council on Exercise
First posted: 2016-11-17
Enrollment: 105
Sex: ALL
Minimum age (years): 8
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of the study was to examine the influence of step goals with pedometers to improve children's weight loss, physical activity, and psychosocial health during behavioral treatment. Children with overweight or obesity were assigned to receive the behavioral treatment alone, plus pedometers, or plus pedometers with step goals.

Detailed description: A total of 105 overweight and obese children ages 8 to 17 years participated in a 10-week family-based weight management intervention focusing on physical activity, nutrition, and behavioral modification. A quasi-experimental design was used to group cohorts into three conditions: two cohorts had no pedometer (n=24); two cohorts had pedometer only (n=25); and four cohorts had pedometer with step goals (i.e. 500 steps/day weekly increase above baseline; n=56). Height and weight were measured at baseline and week 10 and used to calculate body mass index (BMI). Analysis of covariance was performed to examine difference by condition for change in weight, BMI, and BMI z-score, controlling for age and baseline value. Differences in steps/day and psychosocial health were compared between the two pedometer conditions.

Eligibility criteria: Inclusion Criteria:

* Aged 8-17 years old
* BMI ≥ 95th percentile or have a BMI ≥ 85th percentile with comorbidities (e.g. hypertension, heart disease, type 2 diabetes, insulin resistance, sleep apnea, orthopedic problems, or fatty liver disease)

Exclusion Criteria:

* None.

Primary outcomes:
measure: BMI Z-score Change
timeFrame: 10 weeks
Secondary outcomes:
measure: BMI Change
timeFrame: 10 weeks
measure: Body Weight Change
timeFrame: 10 weeks
measure: Quality of Life Kidscreen-10 Index Change
timeFrame: 10 weeks
measure: Physical Activity Enjoyment Change
timeFrame: 10 weeks
measure: Subjective Health Change
timeFrame: 10 weeks
measure: Physical Activity Change
timeFrame: 10 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Pennington Biomedical Research Center
name: Amanda E Staiano, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Staiano AE, Beyl RA, Hsia DS, Jarrell AR, Katzmarzyk PT, Mantzor S, Newton RL Jr, Tyson P. Step Tracking with Goals Increases Children's Weight Loss in Behavioral Intervention. Child Obes. 2017 Aug;13(4):283-290. doi: 10.1089/chi.2017.0047. Epub 2017 Apr 25.
Clinical trial NCT06640829: Added Sugar Intake and Brain Structure and Function
Official title: Added Sugar Intake and Brain Structure and Function
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Child Development
Keywords: Added sugars
Dietary intake
Brain health
Child development
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: Center for Children's Healthy Lifestyles & Nutrition
First posted: 2024-10-15
Enrollment: 65
Sex: ALL
Minimum age (years): 5
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Participants received an invitation to participate in this study if they were enrolled in the ADORE GAINS study as an infant and toddler.

Brief summary: The purpose of this study is to learn if there is a relationship between added sugar intake during pregnancy, infancy, and toddlerhood and the brain's structure and function at 5-6 years old.


Eligibility criteria: Inclusion Criteria:

* Participated in the ADORE GAINS study (R01 DK118220).
* Age at participation 5-6 years old.

Exclusion Criteria:

* Did not participated in the ADORE GAINS study.
* Younger than 5 and older than 6.
* Autism diagnosis

Primary outcomes:
measure: Added sugars intake relationship to brain structure
timeFrame: 5-6 years old
measure: Added sugars intake relationship to brain function
timeFrame: 5-6 years old
measure: Fructose intake relationship to brain structure
timeFrame: 5-6 years old
measure: Fructose intake relationship to brain function
timeFrame: 5-6 years old
Secondary outcomes:
measure: Added sugars intake relationship to cognition specifically attention development
timeFrame: 5-6 years old
measure: Added sugars intake relationship to cognition specifically vocabulary receptiveness
timeFrame: 5-6 years old
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: The University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: The University of Kansas Medical Center
name: Holly Hull, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04146129: A Phase 1 Study of CDX-0159
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Keywords: CDX-0159
Lead sponsor: Celldex Therapeutics
Sponsor class: INDUSTRY
First posted: 2019-10-31
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study to determine the safety of CDX-0159 in healthy subjects.

Detailed description: CDX-0159 is a humanized monoclonal antibody that binds to a protein called KIT that is expressed on mast cells.

This study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 in healthy subjects.

Eligibility criteria: Key Inclusion Criteria:

* An informed consent signed and dated by the subject.
* Healthy volunteer aged 18-55.
* In generally good health and without significant medical conditions based on physical exam, ECG, and laboratory test results.
* Body mass index (BMI) ≥ 18.5 kg/m2 to ≤ 30 kg/m2
* No medication other than mild analgesics, vitamins and mineral supplements or, oral contraceptives
* Both males and females of child bearing potential must agree to use a medically accepted contraceptive regimen during study and up to 150 days afterwards.
* Not a current smoker (or regular user of any nicotine containing product).
* Willing to follow all study rules

Key Exclusion Criteria:

* Women who are pregnant or nursing
* History of anaphylaxis, food allergies, or allergies (chronic or seasonal) requiring prescription medication
* Autoimmune disorders requiring more than topical medication
* History of asthma requiring the use of inhaled medication within the past 5 years.
* Vaccination with live vaccines within 4 weeks prior to study drug administration (subjects must agree to avoid vaccination during the study).
* Positive urine test for alcohol and drugs of abuse.

Other Protocol defined inclusion and exclusion criteria could apply.

Primary outcomes:
measure: Safety as assessed by CTCAE v5.0
timeFrame: Day 1 to Day 43.
Secondary outcomes:
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Altasciences Clinical Kansas, Inc.
state: Kansas
Study officials:
References:
Clinical trial NCT05619029: Study to Evaluate the Effectiveness of the Device in Detection of Abnormal Findings on X-ray
Official title: Retrospective, Observer-blinded, Pivotal Study to Evaluate the Effectiveness of the Investigational Device (Lunit INSIGHT CXR) in Detection of Abnormal Findings on Chest Radiographs
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Disease
Lead sponsor: Lunit Inc.
Sponsor class: INDUSTRY
First posted: 2022-11-16
Enrollment: 1111
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The secondary hospital patients

Brief summary: This study aims to evaluate the effectiveness of the investigational device (Lunit INSIGHT CXR) in the detection of chest abnormalities.

Detailed description: In the study, the standalone performance of Lunit INSIGHT CXR was primarily assessed by comparing the analysis results from the investigational device and reference standards in the detection of 10 abnormal radiologic findings - atelectasis, calcification, cardiomegaly, consolidation, fibrosis, mediastinal widening, nodule/mass, pleural effusion, pneumoperitoneum, and pneumothorax.

In addition, to investigate the effect of Lunit INSIGHT CXR assistance on the interpreting physician's interpreting performance, a multi-reader, multi-case (MRMC) study was conducted.

Eligibility criteria: Inclusion Criteria:

* Chest radiographs of aged 14 years or older
* Conventional PA or AP chest radiographs
* Chest radiographs with confirmed radiology reports

Exclusion Criteria:

* Chest radiographs taken in postures other than PA and AP e.g.) decubitus, oblique, lordotic, or lateral view
* Invert-grayscale chest radiographs
* Image quality not suitable for interpretation due to incorrect patient positioning, inadequate image collimation, severely damaged lung presence of external materials such as jewelry

Primary outcomes:
measure: Area Under the Receiver Operating Characteristic Curve (ROC AUC) of the investigational device in detection of overall target radiologic findings
timeFrame: Through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: SMG-SNU Boramae Medical Center
Study officials:
References:
Clinical trial NCT00586729: Vashe Wound Therapy Study
Official title: Pilot Study to Evaluate Effectiveness of Vashe™ Wound Therapy as an Antimicrobial Irrigant in Burn Wound Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burns
Keywords: Burn
Burn wound management
Burn graft
Lead sponsor: Valleywise Health
Sponsor class: OTHER
Collaborators: name: PuriCore, Inc.
First posted: 2008-01-04
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy, safety, and tolerability of topical Vashe™ Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist versus 5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.


Eligibility criteria: Inclusion Criteria:

* Male or female, aged 18 years and over requiring hospitalization for burn injury
* Burn injury requiring wound excision and auto-grafting
* Less than or equal to 20% Total Body Surface Area burns

Exclusion Criteria:

* Pregnant or lactating females
* Individuals with chlorine sensitivity
* Electrical, chemical and cold injury
* Burns to the face, hands, feet and or perineum area
* Steroid therapy

Primary outcomes:
measure: Percentage of Grafted Area That is Viable at Day 14
timeFrame: 14 days
Secondary outcomes:
measure: Length of Stay
timeFrame: 0 days, 3 days, 5 days and 14 days post-operation
measure: Hospital Cost Per Patient
timeFrame: Volume used from admission to discharge
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Maricopa Integrated Health System
state: Arizona
Study officials:
affiliation: District Medical Group
name: Kevin Foster, MD
role: PRINCIPAL_INVESTIGATOR
References: